1. Simulations Plus CEO Shawn O'Connor participates in key investor events. 2. Events include Wells Fargo Healthcare Conference on September 3-4, 2025. 3. Shawn O'Connor will also attend Morgan Stanley's conference on September 10, 2025. 4. Simulations Plus offers bioinformatics and biosimulation solutions in biopharma. 5. Company focuses on advanced AI/ML technologies and medical communications.
Participation in major investor events often boosts investor confidence and visibility, enhancing potential market interest. Historically, similar events have positively influenced stock performance of tech companies in the biotech sector.
The article details significant events that can enhance market visibility, potentially increasing investor interest. Events that showcase leadership and innovation typically resonate with market movements.
Investor events typically yield immediate short-term impacts on stock price. This can catalyze interest and trading activity leading up to and following the events.
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the following investor events in September:
2025 Wells Fargo Healthcare Conference
Format: Fireside chat and one-on-one meetings
When: Wednesday and Thursday, September 3-4, 2025
Location: Boston, Massachusetts
Webcast Link: Wednesday, September 3, 2025 at 12:45 PM ET here
Morgan Stanley 23rd Annual Global Healthcare Conference
Format: Fireside chat and one-on-one meetings
When: Wednesday, September 10, 2025
Location: New York City
Webcast Link: Wednesday, September 10, 2025 at 2:35 PM ET here
For more information about the events or questions about registration, interested parties should reach out to their contacts at Wells Fargo and Morgan Stanley.
About Simulations Plus, Inc.
With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250827867971/en/
Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com